Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Shareholder Meeting (November 2018)
27 slides from Proteomics International Laboratories's shareholder meeting presentation, Nov 22, 2018
Slide 1: Annual General Meeting Shareholder Presentation
For personal use only Annual General Meeting Shareholder Presentation 22 November 2018, Perth, Western Australia BUILDING A GLOBAL ASX: PIQ DIAGNOSTICS BUSINESS
Slide 2: Disclaimer
DISCLAIMER For personal use only This Presentation is provided by Proteomics International Laboratories Ltd (PILL, the Company). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding whether or not to se
Slide 3: Building a Global Diagnostics Business
BUILDING A GLOBAL DIAGNOSTICS BUSINESS For personal use only PromarkerD, a predictive test for diabetic kidney disease is being rolled out now. 425m ENORMOUS MARKET adults have diabetes globally. Territories already licenced capture 47m diabetes sufferers. DE-RISKED CLINICALLY PromarkerD clinical st
Slide 4: Corporate Overview
CORPORATE OVERVIEW For personal use only Volume Price CAPITAL STRUCTURE – 21/11/2018 2 0.4 ASX code PIQ Millions Share Price $0.355 1.8 0.35 Shares on issue 80m 1.6 Market capitalisation $28.4m 0.3 Cash/Receivables $3.8m 1.4 Enterprise Value $24.2m 0.25 1.2 Revenue & other income – FY18 $2.2m 1 0.2
Slide 5: Proteomics vs Typical Biotechs
PROTEOMICS Vs TYPICAL BIOTECHS For personal use only ALL THE UPSIDE WITHOUT THE CLINICAL RISKS, COSTS & EXTENDED TIMELINES Features PIQ Typical Biotechs Enormous markets ✓ ✓ Minimal clinical risk ✓ X No waiting for results ✓ X Short clinical development (for new products) ✓ X No binary outcome ✓ X L
Slide 6: The Promarker Technology
THE PROMARKER TECHNOLOGY For personal use only PLATFORM TECHNOLOGY : PROMARKERTM PromarkerD – DIABETIC KIDNEY DISEASE TEST ANALYTICAL SERVICES ▪ PromarkerD – predictive test for diabetic kidney ▪ Best in class Quality Control testing disease up to four years in advance ▪ Biosimilars & biologics ▪ Li
Slide 7: Promarker – Platform Technology
PROMARKER – PLATFORM TECHNOLOGY For personal use only Promarker is platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics to formulate commercial diagnostic tests 7
Slide 8: PromarkerD: Predictive Test for Diabetic Kidney Disease
PromarkerD For personal use only PREDICTIVE TEST FOR DIABETIC KIDNEY DISEASE 8
Slide 9: A Major Opportunity
A MAJOR OPPORTUNITY For personal use only THE PROBLEM 425 million people have diabetes 1 in 3 diabetic adults currently develop chronic kidney disease There are no early symptoms of diabetic kidney disease. Kidney function can fall below 15-20% with no symptoms. There is currently no available test
Slide 10: How It Works
HOW IT WORKS For personal use only PromarkerD is a blood test that measures plasma protein biomarkers combined with simple clinical factors to predict risk of kidney decline in people with type 2 diabetes The test measures a fingerprint of 3 proteins found in a standard blood sample These measuremen
Slide 11: Major Cost/Benefit Factor to Drive Uptake
MAJOR COST/BENEFIT FACTOR TO DRIVE UPTAKE For personal use only With PromarkerD Without PromarkerD Unequivocal Cost Benefit Test Price US$50 – US$70 Dialysis cost US$72,000 per year Predicts kidney disease with 86% VS ongoing for the patient’s life accuracy up to four years out Unequivocal Patient B
Slide 12: Validation Complete
VALIDATION COMPLETE For personal use only PromarkerD developed and validated in clinical studies of 792 patients with diabetes Eight year clinical journey complete - minimal clinical risk - 86% Accurate Study - 1,500 people over 6 years with UWA presented to American Diabetes Association Results pee
Slide 13: Two Types of Tests to Capture Mass Market
TWO TYPES OF TESTS TO CAPTURE MASS MARKET For personal use only LABORATORY DEVELOPED TEST (“LDT”) KIT VERSION ▪ Utilises ‘mass spectrometry’ to identify specific ▪ Immunoassay kit that utilises ‘key antibody biomarkers of proteins reagents’ to identify the specific biomarker proteins ▪ Mass spectrom
Slide 14: Market Size? Undiagnosed
50% Nth America & Caribbean MARKET SIZE? UNDIAGNOSED Africa Europe For personal use only South & Central America South-East Asia ➢ Hundreds of millions of Middle East & North Africa people could benefit from Western Pacific this test in terms of early Africa treatment to mitigate the Sth/Ctrl Americ
Slide 15: Commercial Rollout – Sales Imminent
COMMERCIAL ROLLOUT – SALES IMMINENT For personal use only Deal executed: Aug 16 Deal executed: May 18 Deal executed: June 18 Deal executed: Oct 18 REVENUES EXPECTED TO FLOW ~6 MONTHS POST TRANSACTION 15
Slide 16: The Deal: USA License
THE DEAL LICENSING DEAL: USA license agreement with PrismHealthDx, Inc. – Executed May 2018 For personal use only UNITED STATES Africa of PromarkerD South & The license is for the “Laboratory Developed Test” version Central America Middle East National launch and first revenues imminent & North Afri
Slide 17: The Deal: Mexico License
THE DEAL LICENSING DEAL: Mexico license agreement with Patia Biopharma – Executed June 2018 For personal use only License deal brokered by Carlos Slim Foundation, aAfrica South & supporter of Patia MEXICO Central America Middle East The license is for the “Laboratory Developed Test” version of Proma
Slide 18: The Deal: Spain License
THE DEAL LICENSING DEAL: Spain license agreement with Patia Europe – Executed October 2018 For personal use only Africa of PromarkerD The license is for the “Laboratory Developed Test” version South & SPAIN First sales are anticipated to be within six months Central America Middle East & North Afric
Slide 19: Licensing Deals
LICENSING DEALS For personal use only LICENSING DEALS # DIABETICS LICENSING MODEL United States 30m LICENSING FEES Mexico 13m + Spain 3.6m UPFRONT PAYMENTS Dominican Republic 0.5m + TOTAL 47.1m ROYALTIES PIPELINE Japan 10m India 32m DEALS & PIPELINE China 114m = Puerto Rico 0.4m Australia 1.2m 48.6%
Slide 20: Intellectual Property
Africa Countries with For personal use only South & Patents Trademark Central America INTELLECTUAL granted IP Middle East & North Africa PROPERTY USA ✓ ✓ Europe ✓ Pending Australia ✓ ✓ China ✓ ✓ Japan ✓ ✓ Russia ✓ Singapore ✓ Pending National phase patent examination pending: Brazil, Canada, India a
Slide 21: Further Global Potential in New Markets
FURTHER GLOBAL POTENTIAL IN NEW MARKETS For personal use only Proteomics endeavours to leverage its PromarkerTM Platform DIAGNOSTICS to develop and commercialise a suite of diagnostic tests Potential for faster market adoption for new diagnostic test, PIPELINE post a successful PromarkerD commercial
Slide 22: Analytical Services
ANALYTICAL SERVICES For personal use only REVENUE GENERATING BUSINESS WITH SYNERGIES 22
Slide 23: Analytical Services
ANALYTICAL SERVICES For personal use only WORLD’S FIRST COMPANY TO RECEIVE ISO 17025 LABORATORY ACCREDITATION FOR PROTEOMICS SERVICES Biosimilars & biologics Pharmacokinetic testing (PK) for clinical trials ▪ Assisting pharmaceutical companies develop ▪ Pre-clinical and clinical quantitative assays
Slide 24: Milestones and Upcoming Catalysts
MILESTONES AND UPCOMING CATALYSTS For personal use only ACHIEVED MILESTONES SHARE PRICE CATALYSTS ✓ PromarkerD predictive test clinically proven PromarkerD ✓ Patents granted in USA, China, Europe & Japan Revenue commences from royalties Further licencing deals in major territories ✓ PromarkerD resul
Slide 25: Exceptional Global Opportunity
EXCEPTIONAL GLOBAL OPPORTUNITY For personal use only ✓ A proven diagnostics business with truly global potential ✓ Scalable licensing model with high margins and negligible rollout cost ✓ Minimal burn rate ensures rollout is funded – Established revenue reduces burn, trending to cash flow positive ✓
Slide 26: Board & Management
BOARD & Terry Sweet FAICD, Chairman Director of several listed companies over the past 30 years in both executive and non-executive MANAGEMENT capacities. Companies include XRF Scientific Ltd, where he was Africa Biotechnology Ltd, Heartlink Ltd, and Scientific Services Ltd. Managing Director for 4
Slide 27: Contact
CONTACT For personal use only Richard Lipscombe Dirk van Dissel Managing Director Corporate Advisor & Investor Relations T: +61 8 9389 1992 Adelaide Equity Partners E: r.lipscombe@proteomicsinternational.com T: +61 8 8232 8800 www.proteomicsinternational.com E: dvandissel@adelaideequity.com.au ASX:
Proteomics International Laboratories — Shareholder Meeting (November 2018) on 6ix